Myriad Genetics, Inc. (MYGN) stock forecast & analysis
5.54
NasdaqGS · USDDelayed by 15 minutes
Up: +1.33, +31.6%
5.66Up: +0.12, +2.2%
1 analysis
Latest analysis: · verdict locked
- Open
- 5.34
- Previous close
- 4.21
- Day range
- 5.25 – 5.95
- 52-week range
- 2.74 – 8.50
- Volume (shares)
- 23.91M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 95.65M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.64
- Market cap
- 529.90M
Market Scanner’s AI analysis of Myriad Genetics, Inc. (MYGN), updated October 2026: Myriad Genetics' recent surge driven by prenatal unit sale and analyst upgrade, despite ongoing revenue decline and unprofitability.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Myriad Genetics, Inc. (MYGN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Myriad Genetics' recent surge driven by prenatal unit sale and analyst upgrade, despite ongoing revenue decline and unprofitability.
Recent analyses for Myriad Genetics (MYGN) covered a significant stock price increase, attributed to the sale of its prenatal unit and a Piper Sandler upgrade. The market analyst report noted strong short-term technical momentum, with the price trading above key moving averages and Bollinger Bands, though RSI and MFI indicated overbought conditions. The fundamentals analyst highlighted a year-over-year revenue decrease, ongoing unprofitability, and a decline in shareholder equity, alongside adequate short-term liquidity.
MYGN news & sentiment
News reports highlighted positive momentum for Myriad Genetics, driven by a significant asset sale and a favorable analyst rating change. Social media discussion was not covered in the provided notes.
MYGN technical picture
The stock price has shown a strong recent uptrend, trading significantly above its 50-day and 200-day simple moving averages and the upper Bollinger Band, indicating potential overextension. Momentum indicators like the MACD are positive, while RSI and MFI suggest overbought conditions with strong buying pressure.
Fundamentals
The company's revenue has shown a year-over-year decrease. Myriad Genetics is currently unprofitable, with negative profit margins and earnings per share. While debt is present, short-term liquidity appears adequate based on current and quick ratios. Shareholder equity has also decreased over the recent period.
Factors discussed — upside
- Stock price trading significantly above 50-day and 200-day simple moving averages.
- Strong 7-day and 30-day price changes indicating recent uptrend.
- Positive MACD suggesting bullish momentum.
- Sale of prenatal unit for $210 million.
- Analyst upgrade from Underweight to Neutral.
Factors discussed — risks
- Year-over-year revenue decrease of 10.5%.
- Company is currently unprofitable with negative profit margin and EPS.
- Negative Return on Equity.
- Total shareholder equity has decreased significantly.
- RSI and MFI indicate overbought territory.
- Technical Momentum
- Financial Performance
- Asset Sale
- Analyst Ratings
Summary updated .
MYGN technical indicators
Common technical indicators for MYGN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 3.73 | Price above |
| 10-day exponential moving average | 4.43 | Price above |
| Relative strength index (14-day) | 72.26 | Overbought |
| MACD line (12/26/9) | 0.1977 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 3.65 – 4.94 | Price above the upper band |
Analyses
Recent MYGN.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-20 MYGN.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Myriad Genetics, Inc.?
- The bull case for Myriad Genetics centers on significant recent stock price appreciation, driven by the sale of its prenatal unit and a favorable analyst upgrade. Technical indicators also suggest strong short-term momentum, with the price trading above key moving averages and exhibiting positive MACD readings.
- What are the risks for Myriad Genetics, Inc.?
- Risks for Myriad Genetics include a year-over-year revenue decrease and ongoing unprofitability, evidenced by negative profit margins and earnings per share. Furthermore, the company has experienced a significant decline in shareholder equity, and current technical indicators suggest the stock may be overbought.
- Is Myriad Genetics, Inc. bullish or bearish?
- Recent AI analyses of Myriad Genetics, Inc. examined factors on both sides. Discussed upside: The bull case for Myriad Genetics centers on significant recent stock price appreciation, driven by the sale of its prenatal unit and a favorable analyst upgrade. Technical indicators also suggest strong short-term momentum, with the price trading above key moving averages and exhibiting positive MACD readings. Discussed risks: Risks for Myriad Genetics include a year-over-year revenue decrease and ongoing unprofitability, evidenced by negative profit margins and earnings per share. Furthermore, the company has experienced a significant decline in shareholder equity, and current technical indicators suggest the stock may be overbought. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Myriad Genetics, Inc.?
- News reports highlighted positive momentum for Myriad Genetics, driven by a significant asset sale and a favorable analyst rating change. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Myriad Genetics, Inc.?
- Every analysis of Myriad Genetics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Myriad Genetics, Inc.?
The bull case for Myriad Genetics centers on significant recent stock price appreciation, driven by the sale of its prenatal unit and a favorable analyst upgrade. Technical indicators also suggest strong short-term momentum, with the price trading above key moving averages and exhibiting positive MACD readings.
What are the risks for Myriad Genetics, Inc.?
Risks for Myriad Genetics include a year-over-year revenue decrease and ongoing unprofitability, evidenced by negative profit margins and earnings per share. Furthermore, the company has experienced a significant decline in shareholder equity, and current technical indicators suggest the stock may be overbought.
Is Myriad Genetics, Inc. bullish or bearish?
Recent AI analyses of Myriad Genetics, Inc. examined factors on both sides. Discussed upside: The bull case for Myriad Genetics centers on significant recent stock price appreciation, driven by the sale of its prenatal unit and a favorable analyst upgrade. Technical indicators also suggest strong short-term momentum, with the price trading above key moving averages and exhibiting positive MACD readings. Discussed risks: Risks for Myriad Genetics include a year-over-year revenue decrease and ongoing unprofitability, evidenced by negative profit margins and earnings per share. Furthermore, the company has experienced a significant decline in shareholder equity, and current technical indicators suggest the stock may be overbought. These are descriptive observations, not a recommendation.
What is the latest sentiment on Myriad Genetics, Inc.?
News reports highlighted positive momentum for Myriad Genetics, driven by a significant asset sale and a favorable analyst rating change. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Myriad Genetics, Inc.?
Every analysis of Myriad Genetics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh MYGN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.